Health Care & Life Sciences » Biotechnology | Global Blood Therapeutics Inc.

Global Blood Therapeutics Inc. | Mutual Funds

Mutual Funds that own Global Blood Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
SPDR S&P Biotech ETF
1,590,062
3.06%
4,092
1.33%
09/06/2018
Fidelity Select Biotechnology Portfolio
1,341,143
2.58%
355,100
0.71%
07/31/2018
Fidelity Growth Company Fund
1,246,976
2.4%
193,113
0.13%
07/31/2018
Vanguard Small Cap Index Fund
1,172,996
2.25%
15,268
0.06%
07/31/2018
Vanguard Total Stock Market Index Fund
1,168,761
2.25%
1,334
0.01%
07/31/2018
iShares Russell 2000 ETF
1,056,522
2.02%
-564
0.11%
09/06/2018
Janus Global Life Sciences Fund
962,757
1.85%
121,553
1.15%
06/30/2018
Janus Triton Fund
909,924
1.75%
138,771
0.38%
06/30/2018
Janus Research Fund
758,749
1.46%
0
0.25%
06/30/2018
Vanguard Small Cap Growth Index Fund
670,717
1.29%
11,102
0.13%
07/31/2018

About Global Blood Therapeutics

View Profile
Address
171 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.gbt.com
Updated 07/08/2019
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.